We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.
- Authors
Valero, Vicente; Forbes, John; Pegram, Mark D; Pienkowski, Tadeusz; Eiermann, Wolfgang; von Minckwitz, Gunter; Roche, Henri; Martin, Miguel; Crown, John; Mackey, John R; Fumoleau, Pierre; Rolski, Janusz; Mrsic-Krmpotic, Zrinka; Jagiello-Gruszfeld, Agnieszka; Riva, Alessandro; Buyse, Marc; Taupin, Henry; Sauter, Guido; Press, Michael F; Slamon, Dennis J
- Abstract
Docetaxel-trastuzumab (TH) is effective therapy for HER2-amplified metastatic breast cancer (MBC). Preclinical findings of synergy between docetaxel, carboplatin, and trastuzumab (TCH) prompted a phase III randomized trial comparing TCH with TH in patients with HER2-amplified MBC.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Vol 29, Issue 2, p149
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2010.28.6450